Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025